For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis Ltd (ASX: PXS) chief executive officer Mr Gary Phillips will present at the Proactive CEO Investor Session to be held today, Tuesday 10 November 2020. Mr Phillips will discuss the significance of last week’s US FDA approval of Bronchitol for Pharmaxis and the Company’s focus on its new drug for the bone cancer myelofibrosis that will commence a phase 1c/2 clinical trial next quarter.
The program commences at 12.00 noon (AEST) and will feature fifteen minute presentations from the CEO’s of three companies – Pharmaxis Ltd, Cynata Therapeutics Ltd and Recce Pharmaceuticals Ltd.
Shareholders and investors are invited to participate in this free event. Please register at the Proactive website at https://www.proactiveinvestors.com.au/register/event_details/298#
A recording of the Investor Session will be made available on the Pharmaxis website after the event.
A recording of the Pharmaxis investor call held at 11.00am (AEST) on 2 November 2020 is available here.
Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced details of the clinical development plan for its lead drug pipeline asset being studied for the bone marrow cancer myelofibrosis.
PXS-5505 has already received IND approval and Orphan Drug Designation from the FDA and will proceed to an open label study recruiting up to 42 patients with myelofibrosis in Australia and international sites. PXS-5505 is a pan-LOX inhibitor that seeks to reverse the bone marrow fibrosis that drives morbidity and mortality in the disease.Read full media release - pdf